title: Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
abstract: BACKGROUND
  It remains unclear whether cilostazol, which has been shown to improve the clinical outcomes of endovascular therapy for femoropopliteal lesions, also reduces angiographic restenosis.
  
  
  RESULTS
  The Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study investigated whether cilostazol reduces the 12-month angiographic restenosis rate after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions. Two hundred patients with femoropopliteal lesions treated from March 2009 to April 2011 at 13 cardiovascular centers were randomly assigned 1:1 to receive oral aspirin with or without cilostazol. The primary end point was 12-month angiographic restenosis rate. Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival. Researchers evaluated all follow-up data and assessed the end points in a blinded fashion. The mean lesion length and reference vessel diameter at the treated segment were 128±86 mm and 5.4±1.4 mm, respectively. The frequency of stent used was similar between groups (88% versus 90% in the cilostazol and noncilostazol group, respectively, P=0.82). During the 12-month follow-up period, 11 patients died and 152 patients (80%) had evaluable angiographic data at 12 months. The angiographic restenosis rate at 12 months was 20% (15/75) in the cilostazol group versus 49% (38/77) in the noncilostazol group (P=0.0001) by intention-to-treat analysis. The cilostazol group also had a significantly higher event-free survival at 12 months (83% versus 71%, P=0.02), although cardiovascular event rates were similar in both groups.
  
  
  CONCLUSIONS
  Cilostazol reduced angiographic restenosis after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions.
  
  
  BACKGROUND
  URL: http://www.clinicaltrials.gov. Unique identifier: NCT00912756; and URL: https://www.umin.ac.jp. Unique identifier: UMIN000002091.
authors: Kansai Rosai Hospital, Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, Hyogo 660-8511, Japan. iida.osa@gmail.com
authors: Osamu
authors: O
authors: Iida
authors: Hiroyoshi
authors: H
authors: Yokoi
authors: Yoshimitsu
authors: Y
authors: Soga
authors: Naoto
authors: N
authors: Inoue
authors: Kenji
authors: K
authors: Suzuki
authors: Yoshiaki
authors: Y
authors: Yokoi
authors: Daizo
authors: D
authors: Kawasaki
authors: Kan
authors: K
authors: Zen
authors: Kazushi
authors: K
authors: Urasawa
authors: Yoshiaki
authors: Y
authors: Shintani
authors: Akira
authors: A
authors: Miyamoto
authors: Keisuke
authors: K
authors: Hirano
authors: Yusuke
authors: Y
authors: Miyashita
authors: Taketsugu
authors: T
authors: Tsuchiya
authors: Norihiko
authors: N
authors: Shinozaki
authors: Masato
authors: M
authors: Nakamura
authors: Takaaki
authors: T
authors: Isshiki
authors: Toshimitsu
authors: T
authors: Hamasaki
authors: Shinsuke
authors: S
authors: Nanto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D017130:Angioplasty; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D000077407:Cilostazol; D003251:Constriction, Pathologic; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011150:Popliteal Artery / Q000000981:diagnostic imaging / Q000473:pathology; D011446:Prospective Studies; D011859:Radiography; D012008:Recurrence; D016037:Single-Blind Method; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000497:Alloys; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; C013616:nitinol; D000077407:Cilostazol; D001241:Aspirin
keywords: angioplasty; peripheral vascular disease; restenosis